Nuvectis Pharma, Inc.
NVCT
$0.20
Change (1 day)
$12.10
Year High
$4.61
Year Low
Categories
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
P/B ratio for Nuvectis Pharma, Inc. (NVCT)
P/B ratio as of 2023: 10.63
According to Nuvectis Pharma, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.63. At the end of 2022 the company had a P/B ratio of 6.68.
P/B ratio history for Nuvectis Pharma, Inc. from 2020 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 10.63 |
| 2022 | 6.68 |
| 2021 | -3.75 |
| 2020 | -4133.28 |